{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lucas JT"],"funding":["National Cancer Institute","American Lebanese Syrian Associated Charities","NCI NIH HHS"],"pagination":["1166-1175"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9248404"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(7)"],"pubmed_abstract":["<h4>Background</h4>We characterize the patterns of progression across medulloblastoma (MB) clinical risk and molecular subgroups from SJMB03, a Phase III clinical trial.<h4>Methods</h4>One hundred and fifty-five pediatric patients with newly diagnosed MB were treated on a prospective, multi-center phase III trial of adjuvant radiotherapy (RT) and dose-intense chemotherapy with autologous stem cell transplant. Craniospinal radiotherapy to 23.4 Gy (average risk, AR) or 36-39.6 Gy (high risk, HR) was followed by conformal RT with a 1 cm clinical target volume to a cumulative dose of 55.8 Gy. Subgroup was determined using 450K DNA methylation. Progression was classified anatomically (primary site failure (PSF) +/- distant failure (DF), or isolated DF), and dosimetrically.<h4>Results</h4>Thirty"],"journal":["Neuro-oncology"],"pubmed_title":["Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study."],"pmcid":["PMC9248404"],"funding_grant_id":["P30 CA021765","R25 CA023944"],"pubmed_authors":["Harreld JH","Klimo P","Huang J","Northcott PA","Ellison DW","Onar-Thomas A","Robinson GW","Tinkle CL","Tumlin P","Merchant TE","Lucas JT","Becksfort JB","Srinivasan S","Boop FA","Orr BA","Krasin MJ","Gajjar A"],"additional_accession":[]},"is_claimable":false,"name":"Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.","description":"<h4>Background</h4>We characterize the patterns of progression across medulloblastoma (MB) clinical risk and molecular subgroups from SJMB03, a Phase III clinical trial.<h4>Methods</h4>One hundred and fifty-five pediatric patients with newly diagnosed MB were treated on a prospective, multi-center phase III trial of adjuvant radiotherapy (RT) and dose-intense chemotherapy with autologous stem cell transplant. Craniospinal radiotherapy to 23.4 Gy (average risk, AR) or 36-39.6 Gy (high risk, HR) was followed by conformal RT with a 1 cm clinical target volume to a cumulative dose of 55.8 Gy. Subgroup was determined using 450K DNA methylation. Progression was classified anatomically (primary site failure (PSF) +/- distant failure (DF), or isolated DF), and dosimetrically.<h4>Results</h4>Thirty","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-22T11:17:07.821Z","creation":"2025-04-05T23:54:09.392Z"},"accession":"S-EPMC9248404","cross_references":{"pubmed":["34894262"],"doi":["10.1093/neuonc/noab284"]}}